IP Library Granted Patent US 11,254,713
Granted Patent B2
US 11,254,713 · App. 15/968,517 · Granted Feb 22, 2022

Method to enhance immunogenicity of live typhoid vaccines and carriers

Inventors: Kenneth Roland (Mesa, AZ); Amanda M. Tafoya (Laveen, AZ)
Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
C07K14/255A61K39/0275A61K2039/522
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,254,713
App. No.
15/968,517
Granted
Feb 22, 2022
Kind
B2
Abstract

In certain embodiments, a recombinant attenuated derivative of a pathogenic Salmonella enterica serovar typhi cell is provided, (a) wherein one or more genes encoding subunits of a stg operon ( Salmonella typhi Δstg) are inactivated or deleted resulting in a decrease of Stg adhesin/fimbriae production as compared to genes encoding a wild-type Stg operon (stgABCC′D), and/or (b) the cell comprises a nucleic acid encoding at least one of a gene encoding a subunit of a long polar fimbriae (Lpf) of S. enterica serovar Typhimurium protein. In certain embodiments, vaccines and compositions, and methods of use of the recombinant attenuated derivative of a pathogenic Salmonella enterica serovar typhi cell are provided.

Claims (25)

1. A recombinant attenuated derivative of a pathogenic Salmonella enterica serovar typhi cell, wherein

(a) one or more genes encoding subunits of a stg operon ( Salmonella typhi Δstg) are inactivated or deleted resulting in a decrease of Stg adhesin/fimbriae production as compared to genes encoding a wild-type Stg operon (stgABCC′D), and

(b) the cell comprises a nucleic acid encoding at least one of a gene encoding a subunit of a long polar fimbriae (Lpf) of S. enterica serovar Typhimurium protein,

wherein the subunit of Lpf is subunit A (lpfA), subunit B (lpfB), subunit C (lpfC), subunit D (lpfD), and/or subunit E (lpfE).

2. The recombinant Salmonella cell of claim 1 , wherein the one or more genes encoding subunits the stg operon are inactivated or deleted.

3. The recombinant Salmonella cell of claim 1 , wherein the at least one of stgA, stgB, stgC, stgC′, stgD are inactivated or deleted.

4. The recombinant Salmonella cell of claim 1 , wherein the decrease of Stg adhesin/fimbriae production is an elimination of Stg adhesin/fimbriae production.

5. A recombinant attenuated derivative of a pathogenic Salmonella enterica serovar typhi cell, wherein

(a) one or more genes encoding subunits of a stg operon ( Salmonella typhi Δstg) are inactivated or deleted resulting in a decrease of Stg adhesin/fimbriae production as compared to genes encoding a wild-type Stg operon (stgABCC′D), and

(b) the cell comprises a nucleic acid encoding at least one of a gene encoding a subunit of a long polar fimbriae (Lpf) of S. enterica serovar Typhimurium protein,

wherein the one or more genes encoding subunits the Lpf is operably linked to a regulatable promoter.

6. The recombinant bacterium of claim 5 , wherein the regulatable promoter is induced by a sugar.

7. The recombinant bacterium of claim 6 , wherein the sugar is selected from the group consisting of arabinose and rhamnose.

8. The recombinant bacterium of claim 1 , wherein the subunit of Lpf is encoded on a plasmid.

9. The recombinant bacterium of claim 1 , wherein the subunit of Lpf is integrated into a chromosome.

10. The recombinant Salmonella cell of claim 1 , wherein the cell lacks a stg operon (stgABCC′D), and contains an Lpf of S. enterica serovar Typhimurium ( Salmonella typhi Δstg Lpf).

11. The recombinant Salmonella cell of claim 1 , wherein the Lpf has at least 90% identity to SEQ ID NOS: 21, 22, 23, 24, and/or 25.

12. The recombinant Salmonella cell of claim 10 , wherein the Lpf has at least 99% identity to SEQ ID NOS: 21, 22, 23, 24, and/or 25.

13. The recombinant Salmonella cell of claim 10 , wherein the Lpf consists of SEQ ID NOS: 21, 22, 23, 24, and/or 25.

14. The recombinant Salmonella cell of claim 1 , wherein the Salmonella is Ty21a, Ty800, χ9639, χ9640, χ9633, CVD 908, CVD 908-htrA, CVD 909, Ty21a-GAD, MD77, Ty21a-PA-01, Ty21a-Ss or M01ZH09 (also called ZH9).

15. The recombinant Salmonella cell of claim 1 , wherein the cell further comprises one or more virulence genes encoding pab, aroA, aroC, aroD, asdA, dapA, dam, murA, nadA, pncB, galE, pmi, fur, ompR, htrA, hemA, cdt, cya, crp, phoP, phoQ, rfc, rfaH, poxA, galU, guaB, guaA, hfq, msbB, relA, spoT, ssaV, clpP, clpX, gidA, wecA, genes required for type 3 secretion system function in pathogenicity island 2, or wherein one or more genes for effector molecules secreted by a type 3 secretion system are inactivated, down-regulated in vivo or deleted.

16. The recombinant Salmonella cell of claim 14 , wherein the gene required for type 3 secretion system function in pathogenicity island 2 is ssaV.

17. The recombinant bacterium of claim 1 , wherein the cell comprises an lpfABCDE operon, and the lpfABCDE operon is operably linked to a promoter.

18. The recombinant Salmonella cell of claim 17 , wherein the promoter is a regulatable or constitutive promoter.

19. The recombinant Salmonella cell of claim 14 , wherein the recombinant Salmonella cell does not produce Lpf fimbriae, but upon induction of the regulatable promoter, the recombinant Salmonella cell displays Lpf fimbriae.

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 1, 2019
From: ARIZONA STATE UNIVERSITY, TEMPE CAMPUS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 048229/0284 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2018
From: ROLAND, KENNETH; TAFOYA, AMANDA M.
To: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
Reel/Frame 045983/0256 →
Continuity (2)
Provisional Application 62492349 · May 1, 2017
Related Publication 20180312550A1 · Nov 1, 2018